MRK · Merck & Company, Inc.
$131.07
+0.81% last session
End-of-day data · updated 2026-07-28
Market cap
$323B
Enterprise value
$366B
Trailing P/E
36.8
Forward P/E
13.5
Dividend yield
3.0%
Beta
0.20
Avg volume
10M
Employees
73K
2D change
—
5D change
0.21%
10D change
2.56%
30D change
1.63%
60D change
10.93%
MTD change
4.30%
YTD change
26.05%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MRK
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-13
Latest call per bank · past 12 months
JP Morgan
Overweight$140
+6.8% vs priceMorgan Stanley
Equal-Weight$113
-13.8% vs priceRBC Capital
Outperform$142
+8.3% vs priceWells Fargo
Overweight$150
+14.4% vs priceBank of America
Buy$141
+7.6% vs priceUBS
Buy$145
+10.6% vs priceCitigroup
Neutral$125
-4.6% vs priceBarclays
Overweight$140
+6.8% vs priceGoldman Sachs
Buy$120
-8.4% vs priceDeutsche Bank
Hold$111
-15.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-13 | JP Morgan | Maintains | Overweight | $135 → $140 |
| 2026-07-13 | BMO Capital | Maintains | Outperform | $135 → $142 |
| 2026-07-13 | Guggenheim | Maintains | Buy | $140 → $145 |
| 2026-07-09 | Morgan Stanley | Maintains | Equal-Weight | $112 → $113 |
| 2026-07-08 | RBC Capital | Reiterates | Outperform | $142 |
| 2026-07-08 | Wells Fargo | Maintains | Overweight | $145 → $150 |
| 2026-07-06 | Cantor Fitzgerald | Reiterates | Neutral | $120 |
| 2026-06-30 | Bank of America | Maintains | Buy | $130 → $141 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 63 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 8.5% above the 50-day MA ($121.48).
- Price vs 200-day MA: Trading 20.2% above the 200-day MA ($109.69).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.36) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($131.82).
MRK Price Chart
Loading chart for MRK…
Fundamentals
About Merck & Company, Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
More in Drug Manufacturers - General
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.